Achieving graft-versus-tumor effect in brain tumor patients: from autologous progenitor cell transplant to active immunotherapy

摘要: Success in treating aggressive brain tumors like glioblastoma multiforme and medulloblastoma remains challenging, part because these malignancies overcome CNS immune surveillance. New insights into tumor immunology have led to a rational development of immunotherapeutic strategies, including cytotoxic Tlymphocyte therapies dendritic cell vaccines. However, are most effective when applied setting minimal residual disease, so require prior use standard or cytoreduction by surgery. Myeloablative chemotherapy with autologous hematopoietic transplantation (autoHCT) can offer platform upon which different cellular be effectively instituted. Specifically, this approach provides an inherent ‘chemical debulking’ through high-dose graft-versus-tumor effect T-cell replete graft. Furthermore, autoHCT may beneficial ‘resetting’ the body’s system, potentially ‘breaking’ tolerance,...